Qlaris Bio, Inc.
Clinical trials sponsored by Qlaris Bio, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drops aim to boost blood flow in diabetic retinopathy and glaucoma Results expected Sep 2026 (estimated)
-
New eye drop combo aims to lower pressure in glaucoma patients
Disease control CompletedThis study tests a new preservative-free eye drop combination (QLS-111-FDC) to lower eye pressure in people with open-angle glaucoma or ocular hypertension. About 60 adults with mild to moderate disease will receive the treatment. The goal is to see if it safely reduces eye press…
Phase 2/3 • Sponsor: Qlaris Bio, Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New eye drop shows promise for glaucoma without high pressure
Disease control CompletedThis study tested a new eye drop called QLS-111 in 37 people with normal tension glaucoma, a type of glaucoma where eye pressure is not high but vision still gets damaged. The goal was to see if QLS-111 is safe and can lower eye pressure better than a standard drop called timolol…
Phase 2 • Sponsor: Qlaris Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC